TNYA · Tenaya Therapeutics, Inc.

Tenaya Therapeutics reported Q1 FY2026 results showing meaningful year-over-year loss narrowing, with operating income at -$20.1 million versus -$27.5 million in the prior year, a 27.1% improvement on an absolute basis. This reflects ongoing cost discipline following the 2025 Workforce Reduction, as the company manages its clinical-stage biotech profile with limited revenue generation. Net income followed suit at -$19.3 million, 28.3% better than the -$26.9 million loss last year, while diluted EPS advanced to -$0.09 from -$0.24, a 62.5% improvement. These gains stem from the company's disciplined approach to R&D and G&A spend in a capital-constrained environment typical for biotechs advancing gene therapies like TN-201 and TN-401.

Liquidity remains a cornerstone, with management affirming existing cash and cash equivalents suffice for working capital and capex needs through at least the next twelve months from the March 31, 2026 period end. Since inception, Tenaya has generated limited collaboration revenue and no product sales, incurring significant net losses and negative operating cash flows due to R&D investments. Future losses are expected, with risks around product development timelines impacting working capital needs and profitability prospects. This positions the company to fund clinical milestones without immediate dilution, though biotech uncertainties persist.